medigraphic.com
ISSN 0185-6014 (Impreso)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2005, Número 1

<< Anterior Siguiente >>

Rev Mex Patol Clin Med Lab 2005; 52 (1)


TrkB: posible blanco en la terapia del neuroblastoma

Díaz-Rosales JD, Loera OF, Romo JE, Ortiz-Morales L

Idioma: Español
Referencias bibliográficas: 20
Paginas: 13-17
Archivo PDF: 92.70 Kb.


RESUMEN

Los neuroblastomas que expresan altos niveles de la proteína transmembrana TrkB y del factor neurotrófico derivado de cerebro (BDNF) están asociados con un mal pronóstico. Diversos estudios indican que BDNF/TrkB son capaces de disminuir la quimiosensibilidad del tumor a los agentes usados en la quimioterapia. Es evidente que la dupla BDNF/TrkB contribuye de manera directa a la quimiorresistencia de estos tumores y que la inhibición de fosfatidil-inositol 3 cinasa (PI-3K) podría mejorar la acción de la quimioterapia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Nakagawara A, Liu X-G, Ikegaki N, White PS, Yamashiro DJ, Nycum LM et al. Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics 1995; 25: 538-546.

  2. Valent A, Danglot G, Bernheim A. Mapping of the tyrosine kinase receptors trkA (NTRK1), trkB (NTRK2) and trkC (NTRK3) to human chromosomes 1q22, 9q22 and 15q25 by fluorescence in situ hybridization. Europ J Hum Genet 1997; 5: 102-104.

  3. Nakagawara A. Trk receptor tyrosine kinases: A bridge between cancer and neural development. Cancer Letters 2001; 169: 107-114.

  4. Yano H, Chao MV. Neurotrophin receptor structure and interactions. Pharma Acta Helve 2000; 74: 253-260.

  5. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM. Resistance to chemotherapy mediated by TRKB in neuroblastomas. Cancer Res 2002; 62: 6462-6466.

  6. Brodeur G, Pritchard J, Berthold F, Cansen N, Castel V. Revision of the international criteria for neuroblastoma diagnosis, stating and response to treatment. J Clin Oncol 1993; 11: 1466-1477.

  7. Israel MA, Hay RJ, Park JG, Gazdar A. Atlas of human tumor cell lines. San Diego: Academic Press, 1994; 42-78.

  8. Jennings RW, LaQuaglia MP, Leong K. Fetal neuroblastoma: prenatal diagnosis and natural history. J Pediatr Surg 1993; 28: 1168-1174.

  9. Azizkhan RG, Haase GM. Current biologic and therapeutic implications in the surgery of neuroblastoma. Semin Surg Oncol 1993; 6: 493-501.

  10. Nakagawara A, Arima M, Azar CG, Scarvarda NJ, Brodeur GM. Inverse relationship between TRK expression and N-myc amplification in human neuroblastomas. Cancer Res 1992; 52: 1364-1368.

  11. Jaboin J, Hong A, Kim CJ, Thiele CJ. Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma. Cancer Letters 2003; 193: 109-114.

  12. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999; 7: 2264-2279.

  13. Lindvall O, Kokaia Z, Bengzon J, Elmer E, Kokaia M. Neurotrophins and brain insults. Trends Neurosci 1994; 17: 490-496.

  14. Middlemas DS, Kihl BK, Moody NM. Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents. J Neurooncol 1999; 45: 27-36.

  15. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3’-kinasa pathway. Cancer Res 2002; 62: 6756-6763.

  16. Evans AE, Kisselbach KD, Liu X, Aggert A, Ikegaki N, Camoratto AM et al. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB. Pediatr Oncol 2001; 36: 181-184.

  17. Nakawara A, Arima-Nakawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-854.

  18. Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ. Expression of brain-derived neurotrophic factor and p145TRKB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 1995; 55: 1798-1806.

  19. Middlemas DS, Kihl BK, Zhou J, Zhu X. Brain-derived neurotrophic factor promotes survival and chemoprotection of human neuroblastoma cells. J Biol Chem 1999; 274: 16451-16460.

  20. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. BDNF activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via PI-3 kinase. Cancer Res 2003; 62: 6756-6763.




2020     |     www.medigraphic.com